Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All IEH Corp filings on SEC EDGAR ↗
IEH Corporation reported record financial results for its second fiscal quarter ended September 30, 2026, with revenue increasing 51% year-over-year to $10.7 million. The company achieved a record backlog exceeding $56 million and returned to profitability with net income of $1.36 million compared to a net loss in the prior year period.
Term
Q2 2027
“As great as this year’s first quarter was, the second quarter exceeded it by every measure. The first quarter’s record revenue of $10 million was eclipsed by this quarter’s $10.7 million. Similarly, our operating profit increased 57%, and our net income and earnings per share both more than doubled.”
Dave Offerman, President and CEO of IEH Corporation
“We shattered our previous backlog record by 40%, and we continue to hire and add capacity and equipment to meet the surge in demand in the defense, commercial aerospace, space and medical markets we serve.”
Dave Offerman, President and CEO of IEH Corporation
IEH Corp reported a significant turnaround for the six months ended September 30, 2026, with revenue increasing to $20.7 million from $13.4 million in the prior year. The company achieved a net income of $2.0 million compared to a net loss of $0.7 million, driven by higher sales volume and a benefit from income taxes.
IEH Corporation entered into a new three-year employment agreement with its CFO, Subrata Purkayastha, effective November 1, 2026. The agreement includes an annual base salary of $293,950, a performance bonus of up to 100% of base salary, and an immediate grant of 35,000 stock options at an exercise price of $29.60.
IEH Wins $3.6M Contract from a leading manufacturer of mobile defibrillators
IEH Corporation received $3.6 million in new orders from a leading medical device manufacturer for its Hyperboloid connectors to be used in mobile defibrillators. This contract represents a strategic expansion into the medical market, diversifying the company's revenue beyond its core defense and aerospace business.